For example, small molecular ATP-competitive ALK inhibitors, which can effectively inhibit the autophosphorylation of ALK protein and suppress downstream signal activation [75, 76], have led to unprecedented survival benefits in EML4-ALK fusion NSCLC patients [77–79]. The gene discussed is EML4; the disease is non-small cell lung carcinoma.